Study drug for adults with relapsed or treatment-resistant lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests dencatistat (STP938) to treat adults whose B-cell or T-cell lymphoma has come back or not responded to treatment. It looks at safety, the best dose, and whether it can shrink tumors or improve disease control when standard options have not helped.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent and follow study visits and procedures
- You have biopsy-confirmed B-cell or T-cell lymphoma that has relapsed or is treatment-resistant
- You’ve had at least two prior cancer treatments and no known options are expected to help
- Your lymphoma has measurable disease on scans/tests (special measurement rules may apply for cutaneous T-cell lymphoma)
- You’re well enough to do daily activities (ECOG 0–2) and have more than 3 months expected life
- Your prior treatment side effects have mostly gone away (back to mild or baseline), and your blood/liver/kidney/clotting tests are acceptable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.